Open Research Studies at the Penn Memory Center

Mr_Pipo_thoughts.svg

The Biogen study is a Phase II clinical research study of the drug aducanumab for individuals age 50-85 with early Alzheimer’s disease, including mild cognitive impairment.

Aducanumab is a human antibody that recognizes some forms of beta-amyloid. The primary objective of the study is to evaluate the efficacy of aducanumab in slowing cognitive and functional impairment. This drug is not FDA-approved and is investigational.

Click here for a one-page handout on Biogen.

A4-Handout-image

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 for short), is a clinical research study for older individuals who may be at risk for Alzheimer’s disease (AD). The A4 study is investigating a drug intervention, solanezumab, and Individuals 65-85 years of age with normal cognition may be eligible. The study requires infusion visits every four weeks, for a total of 42 infusion visits over three consecutive years.

 

Download a one-page overview of this study including contact information

mri-scans

The purpose of the ASL-PET study is to determine the value of a special MRI scan that measures cerebral blood flow (called Arterial Spin Labeled MRI) in the diagnosis of Mild Cognitive Impairment. We will compare this measure with other more established tests: brain imaging with Postiron Emission Tomography (PET/CT) and a lumbar puncture (LP) procedure, which allow researchers to evaluate the quantity of proteins associated with Alzheimer’s Disease.

Individuals 55-89 years of age with a diagnosis of Mild Cognitive Impairment (MCI) or normal controls may be eligible.

Download a one-page overview of the study, including contact information.

Welcome to Penn Memory Center


News and Events

  Earlier this month, Penn Alzheimer’s Disease Core Center Director Dr. John Q. Trojanowski presented a lecture on “Experimental Transmission of
Read More


  A new clinical trial will likely lead to a change in physician management of dementia patients, said Penn Memory Center Co-Director
Read More


  The Penn Healthy Brain Research Center is pleased to co-host the fourth and final installment of an international symposium
Read More


  The United States has taken long strides towards treating and preventing the medical issues associated with Alzheimer’s disease, but
Read More


The Elder Justice Coordinating Council (EJCC) is bringing together leaders in government and research Wednesday morning, and a live stream of
Read More


Penn Memory Center in the Community

Click here to find out about the important work the Penn Memory Center is doing in the Philadelphia community.

 PMC in community

What does it mean to be a caregiver?

Click here to listen to the stories of caregivers from the PMC community.

I am a Caregiver

 

The University of Pennsylvania Prevention Research Center


The University of Pennsylvania Prevention Research Center seeks to advance public health goals, and serves as a hub for interdisciplinary chronic disease prevention research, training, and dissemination at the University of Pennsylvania.

Penn Memory Center's Jason Karlawish, MD, leads one of the PRC's Special Interest Projects - Alzheimer's/Dementia Assessment Messaging - and one of the SIP's Collaborating Networks - The Healthy Brain Research Center.

To read more about the PRC's work, visit their website at http://www.upennprc.org/